Total Payments
$136,787
2024 Payments
$2,429
Companies
53
Transactions
1,421
Medicare Patients
2,829
Medicare Billing
$468,087
Payment Breakdown by Category
Other$93,035 (68.0%)
Food & Beverage$28,959 (21.2%)
Travel$9,799 (7.2%)
Consulting$4,622 (3.4%)
Education$370.56 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93,035 | 73 | 68.0% |
| Food and Beverage | $28,959 | 1,287 | 21.2% |
| Travel and Lodging | $9,799 | 33 | 7.2% |
| Consulting Fee | $4,622 | 5 | 3.4% |
| Education | $370.56 | 23 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $46,192 | 200 | $0 (2024) |
| United Therapeutics Corporation | $37,677 | 119 | $0 (2024) |
| GlaxoSmithKline, LLC. | $21,329 | 324 | $0 (2024) |
| Gilead Sciences, Inc. | $13,376 | 32 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $5,326 | 163 | $0 (2024) |
| GENZYME CORPORATION | $2,338 | 38 | $0 (2024) |
| Insmed, Inc. | $1,572 | 82 | $0 (2024) |
| Genentech USA, Inc. | $1,274 | 72 | $0 (2023) |
| Mylan Specialty L.P. | $989.10 | 45 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $988.48 | 51 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,429 | 92 | AstraZeneca Pharmaceuticals LP ($656.12) |
| 2023 | $4,118 | 107 | GENZYME CORPORATION ($1,560) |
| 2022 | $5,163 | 144 | GlaxoSmithKline, LLC. ($1,627) |
| 2021 | $13,622 | 172 | GlaxoSmithKline, LLC. ($8,738) |
| 2020 | $12,541 | 181 | GlaxoSmithKline, LLC. ($7,182) |
| 2019 | $34,960 | 253 | Boehringer Ingelheim Pharmaceuticals, Inc. ($20,653) |
| 2018 | $37,138 | 234 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15,523) |
| 2017 | $26,815 | 238 | United Therapeutics Corporation ($13,174) |
All Payment Transactions
1,421 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/16/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.91 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $20.52 | General |
| Category: HFCWO | ||||||
| 12/11/2024 | INOGEN, INC. | INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH (Device) | Food and Beverage | Cash or cash equivalent | $19.43 | General |
| Category: OXYGEN CONCENTRATOR | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/04/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: Airway Clearance Device | ||||||
| 12/02/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/26/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: PULMONOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: Immunology | ||||||
| 11/13/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 10/29/2024 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Airway Clearance Device | ||||||
| 10/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: RESPIRATORY | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: Immunology | ||||||
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: Respiratory | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Respiratory | ||||||
| 10/11/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $14.78 | General |
| Category: HFCWO | ||||||
| 10/10/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $5.59 | General |
| Category: HFCWO | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $124.56 | General |
| Category: Respiratory | ||||||
| 10/08/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 974 | 1,769 | $300,160 | $152,426 |
| 2022 | 9 | 921 | 1,809 | $296,078 | $146,608 |
| 2021 | 4 | 377 | 703 | $112,606 | $55,441 |
| 2020 | 6 | 557 | 1,512 | $239,296 | $113,612 |
Total Patients
2,829
Total Services
5,793
Medicare Billing
$468,087
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 325 | 852 | $144,840 | $78,749 | 54.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 82 | 219 | $35,916 | $20,136 | 56.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 163 | 163 | $43,847 | $19,469 | 44.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 84 | 206 | $23,484 | $12,652 | 53.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 93 | 96 | $30,816 | $12,503 | 40.6% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 75 | 77 | $6,622 | $3,370 | 50.9% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 72 | 73 | $6,351 | $3,023 | 47.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 68 | 71 | $7,384 | $2,089 | 28.3% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2023 | 12 | 12 | $900.00 | $436.68 | 48.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 283 | 734 | $124,780 | $68,731 | 55.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 123 | 399 | $45,486 | $21,437 | 47.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 104 | 114 | $36,594 | $17,179 | 46.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 145 | 145 | $39,005 | $17,012 | 43.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 40 | 184 | $30,176 | $14,105 | 46.7% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 73 | 73 | $6,278 | $3,161 | 50.4% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 73 | 73 | $6,351 | $2,867 | 45.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 67 | 67 | $6,968 | $1,818 | 26.1% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2022 | 13 | 20 | $440.00 | $298.35 | 67.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 291 | 442 | $74,618 | $35,921 | 48.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 32 | 207 | $22,849 | $12,090 | 52.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 34 | 34 | $8,904 | $4,177 | 46.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 20 | $6,235 | $3,254 | 52.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 351 | 963 | $162,050 | $74,801 | 46.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 51 | 372 | $40,991 | $21,091 | 51.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 54 | 62 | $19,144 | $9,812 | 51.3% |
About Dr. Thomas Pollard, DO
Dr. Thomas Pollard, DO is a Pulmonary Disease healthcare provider based in Peoria, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710069885.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Pollard, DO has received a total of $136,787 in payments from pharmaceutical and medical device companies, with $2,429 received in 2024. These payments were reported across 1,421 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($93,035).
As a Medicare-enrolled provider, Pollard has provided services to 2,829 Medicare beneficiaries, totaling 5,793 services with total Medicare billing of $468,087. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease
- Location Peoria, AZ
- Active Since 10/19/2006
- Last Updated 09/16/2024
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1710069885
Products in Payments
- NUCALA (Biological) $18,437
- ORENITRAM (Drug) $12,162
- SPIRIVA RESPIMAT (Drug) $10,062
- Letairis (Drug) $8,881
- NONE (Drug) $8,688
- REMODULIN (Drug) $3,289
- DUPIXENT (Biological) $3,170
- Arikayce (Drug) $1,547
- TRELEGY ELLIPTA (Drug) $1,525
- SYMBICORT (Drug) $1,356
- OFEV (Drug) $1,345
- BREZTRI (Drug) $1,175
- STIOLTO RESPIMAT (Drug) $1,110
- FASENRA (Drug) $1,012
- ANORO (Drug) $641.59
- SPIRIVA (Drug) $638.93
- BEVESPI AEROSPHERE (Drug) $556.54
- Yupelri (Drug) $547.73
- Xolair (Biological) $545.32
- TYVASO (Drug) $504.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Peoria
Dr. Jon Michel, Md, MD
Pulmonary Disease — Payments: $65,111
Pulmonary Disease $65,111
Jack Tuber, Do, DO
Pulmonary Disease — Payments: $23,562
Pulmonary Disease $23,562
Gagandip Singh, Md, MD
Pulmonary Disease — Payments: $15,382
Pulmonary Disease $15,382
Shannon Valenzuela, Md, MD
Pulmonary Disease — Payments: $15,216
Pulmonary Disease $15,216
Girish Mehta, Md, MD
Pulmonary Disease — Payments: $14,635
Pulmonary Disease $14,635
Dr. Amit Dhingra, Md, MD
Pulmonary Disease — Payments: $12,770
Pulmonary Disease $12,770